# A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

> **NCT05101317** · PHASE2 · COMPLETED · sponsor: **Hope Medicine (Nanjing) Co., Ltd** · enrollment: 142 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** HMI-115
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05101317
- **Lead sponsor:** Hope Medicine (Nanjing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-11
- **Primary completion:** 2024-09-26
- **Final completion:** 2025-03-19
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101317, "A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05101317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*